Carr Patricia 4

What Happened

• Patricia Carr, SVP and Chief Accounting Officer of Jazz Pharmaceuticals (JAZZ), received 2,370 ordinary shares on January 16, 2026. The reported acquisition price is $0.00 (award delivery), so the filing shows $0 as the purchase amount; market value is not stated in the Form 4.
• This transaction reflects the delivery of performance-based shares granted on March 3, 2023, after the applicable performance vesting conditions were certified on January 16, 2026.

Key Details

• Transaction date: 2026-01-16; Filing date: 2026-01-21 (Form 4 accession 0001784606-26-000002).
• Transaction type/code: A (Award/Grant/Other acquisition).
• Shares acquired: 2,370; Price per share reported: $0.00; Total reported cash outlay: $0.
• Shares owned after the transaction: not specified in the provided filing details.
• Footnote: These are ordinary shares to be delivered pursuant to the performance share awards made March 3, 2023; the level of performance was certified on January 16, 2026 (footnote F1).

Context

• This was an award delivery following satisfaction of performance vesting conditions, not an open‑market purchase or sale. Such compensation-related deliveries are common and reflect prior grant terms rather than a direct buy/sell decision by the insider.
• For retail investors, note that purchases are generally more informative about an insider's market view; awards and compensatory deliveries primarily reflect company pay practices.